SEARCH

SEARCH BY CITATION

References

  • 1
    Rosenberg J, Small EJ. Prostate cancer update. Curr. Opin. Oncol. 2003; 15: 21721.
  • 2
    Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol. 1998; 160: 12209.
  • 3
    Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 150212.
  • 4
    Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 151320.
  • 5
    Issacs JT, Wake N, Coffey DS, Sandberg AA. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res. 1982; 42: 235371.
  • 6
    Sato N, Sadar MD, Bruchovsky N et al. Androgenic induction of prostate-specific antigen gene is repressed by protein–protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J. Biol. Chem. 1997; 272: 1748594.
  • 7
    Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 2002; 277: 707685.
  • 8
    Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 1999; 5: 2805.
  • 9
    Blaszczyk N, Masri BA, Mawji NR et al. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin. Cancer Res. 2004; 10: 18609.
  • 10
    Uehara H, Kim SJ, Karashima T et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J. Natl. Cancer Inst. 2003; 95: 45870.
  • 11
    Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res. 1999; 59: 40304.
  • 12
    Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. 2000; 60: 1706.
  • 13
    Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res. 2000; 60: 305864.
  • 14
    Kiyama S, Morrison K, Zellweger T et al. Castration-induced increase in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res. 2003; 63: 357584.
  • 15
    Rocchi P, So A, Kojima S et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 2004; 64: 6595602.
  • 16
    McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992; 52: 69404.
  • 17
    Nickerson T, Miyake H, Gleave ME, Pollak M. Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor binding proteins. Cancer Res. 1999; 59: 33925.
  • 18
    July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50: 17988.
  • 19
    Miyake H, Monia BP, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense Bcl-xL and antisense Bcl-2 oligodeoxynucleotides plus taxol after castration in the Shionogi tumor model. Int. J. Cancer 2000; 86: 85562.
  • 20
    Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000; 141: 225765.
  • 21
    Blaschuk O, Burdzy K, Fritz IB. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J. Biol. Chem. 1983; 258: 771420.
  • 22
    Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell Biol. 1995; 27: 63345.
  • 23
    Crooke ST. Potential roles of antisense technology in cancer chemotherapy. Oncogene 2000; 19: 66519.
  • 24
    Khuri FR, Kurie JM. Antisense approaches enter the clinic. Clin. Cancer Res. 2000; 6: 160710.
  • 25
    Lebedeva I, Stein CA. Antisense oligonucleotides: promise and reality. Annu. Rev. Pharmacol. Toxicol. 2001; 41: 40319.
  • 26
    Connor J, Buttyan R, Olsson CA, D’Agati V, O'Toole K, Sawczuk IS. SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int. 1991; 39: 1098103.
  • 27
    Kyprianou N, English HF, Davidson NE, Issacs JT. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res. 1991; 51: 1626.
  • 28
    Sensibar JA, Griswold MD, Sylvester SR et al. Prostatic ductal system in rats: regional variation in localization of an androgen-repressed gene product, sulfated glycoprotein-2. Endocrinilogy 1991; 128: 2091102.
  • 29
    Montpeit ML, Lawless KR, Tenniswood M. Androgen-repressed messages in the rat ventral prostate. Prostate 1986; 8: 2536.
  • 30
    Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990; 50: 227582.
  • 31
    Bubendorf L, Kolmer M, Kononen J et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue arrays. J. Natl. Cancer Inst. 1999; 91: 175864.
  • 32
    Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 1990; 50: 374853.
  • 33
    Wright PS, Cross-Doerson D, Th’ng JP et al. A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. Exp. Cell Res. 1996; 222: 54–60.
  • 34
    Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 2000; 60: 254754.
  • 35
    Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 2000; 6: 165563.
  • 36
    Zellweger T, Chi K, Miyake H et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin. Cancer Res. 2002; 8: 327684.
  • 37
    Zellweger T, Kiyama S, Chi K et al. Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumor model. BJU Int. 2003; 92: 4639.
  • 38
    Miyake H, Hara I, Gleave ME, Eto H. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of cluterin and its modulation by androgen. Prostate 2004; 61: 31823.
  • 39
    Yamanaka K, Gleave ME, Hara I, Muramaki M, Miyake H. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol. Cancer Ther . 2005; 4: 18795.
  • 40
    Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. 2001; 7: 424552.
  • 41
    Miyake H, Eto H, Hara I, So A, Li D, Gleave ME. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer KoTCC-1 cells. J. Urol. 2004; 171: 247781.
  • 42
    Miyake H, Yamanaka K, Muramaki M, Hara I, Gleave ME. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia 2005; 7: 1719.
  • 43
    Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the anti-apoptotic gene clusterin. Neoplasia 2001; 3: 3607.
  • 44
    July LV, Beraldi E, So AI et al. Nucleotide-based therapies targeting clusterin chemosensitizes human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 2004; 3: 22332.
  • 45
    Steinberg J, Oyasu R, Lang S et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 1997; 3: 170711.
  • 46
    Pins MR, Fiadjoe JE, Korley F et al. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason score: a preliminary report. Prostate Cancer Prostatic Dis. 2004; 7: 2438.
  • 47
    Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 2000; 157: 3939.
  • 48
    Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res. 2001; 61: 386976.
  • 49
    Miyake H, Gleave M, Kamidono S, Hara I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 2002; 59: 1504.
  • 50
    Miyake H, Hara S, Arakawa S, Kamidono S, Hara I. Overexpression of clusterin is an independent prognostic factor for non-papillary renal cell carcinoma. J. Urol. 2002; 167: 703706.
  • 51
    Schwochau GB, Nath KA, Rosenberg ME. Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int. 1998; 53: 164753.
  • 52
    French LE, Sappino AP, Tschopp J, Schifferli JA. Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. J. Clin. Invest. 1992; 90: 191925.
  • 53
    French LE, Wohlwend A, Sappino AP, Tschopp J, Schifferli JA. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J. Clin. Invest. 1994; 93: 87784.
  • 54
    Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J. Biol. Chem. 1999; 274: 687581.
  • 55
    Carvellera M, Raschella G, Santilli G et al. Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J. Biol. Chem. 2000; 275: 2105560.
  • 56
    Takahashi M, Lin YM, Nakamura Y, Furukawa Y. Isolation and characterization of a novel gene CLUAP1 whose expression is frequently upregulated in colon cancer. Oncogene 2004; 9: 928994.
  • 57
    Michel D, Chatelain G, North S, Brun G. Stress-induced transcription of the clusterin/apo J gene. Biochem. J. 1997; 328: 4550.
  • 58
    Reddy KB, Jin G, Karode MC, Harmony JA, Howe PH. Transforming growth factor beta (TGF-beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry 1996; 35: 615763.
  • 59
    O'Sullivan J, Whyte L, Drake J, Tenniswood M. Alternations in the post-translational modification and intracellular trafficking of clusterin in MCF-7 cells during apoptosis. Cell Death Differ. 2003; 10: 91427.
  • 60
    Yang CR, Leskov K, Hosley-Eberlein K et al. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc. Natl. Acad. Sci. USA 2000; 97: 590712.
  • 61
    Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004; 23: 2298304.
  • 62
    Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 2003; 278: 11590600.
  • 63
    Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S. Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res. 2004; 64: 617482.
  • 64
    Scaltriti M, Bettuzzi S, Sharrard RM, Caporali A, Caccamo AE, Maitland NJ. Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br. J. Cancer 2004; 91: 184250.
  • 65
    Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, Yeatman TJ. Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res. 2004; 64: 741219.
  • 66
    Criswell T, Klokov D, Beman M, Lavik JP, Boothman DA. Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein. Cancer Biol. Ther. 2003; 2: 37280.
  • 67
    Debure L, Vayssiere JL, Rincheval V, Loison F, Drean Y, Michel D. Intracellular clusterin causes juxtanuclear aggregate formation and mitochondrial alternation. J. Cell Sci. 2003; 116: 310921.
  • 68
    Jones SE, Jomary C. Clusterin. Int. J. Biochem. Cell Biol. 2002; 34: 42731.
  • 69
    Wu AJ, Park II, Zhaung L, Lee C. Response to a lethal dose of heat shock by a transient up-regulation of clusterin expression followed by down-regulation and apoptosis in prostate and bladder cancer cells. Prostate 2002; 53: 27785.
  • 70
    Sensibar JA, Sutkowski DM, Raffo A et al. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res. 1995; 55: 24317.
  • 71
    Miyake H, Hara I, Kamidono S, Gleave ME, Eto H. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol. Rep. 2003; 10: 46973.
  • 72
    Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 2004; 64: 183442.
  • 73
    Dash P, Lotan I, Knapp M, Kandel ER, Goelet P. Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc. Natl. Acad. Sci. USA 1987; 84: 7896900.
  • 74
    Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 1993; 90: 86737.
  • 75
    McManaway ME, Neckers LM, Loke SL et al. Tumor-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990; 335: 80811.
  • 76
    Westermann P, Gross B, Hoinkis G. Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides. Biomed. Biochim. Acta 1989; 48: 8593.
  • 77
    Baker BF, Miraglia L, Hagedorn CH. Modulation of eukaryotic initiation factor-4E binding to 5′-capped oligoribonucleotides by modified antisense oligonucleotides. J. Biol. Chem. 1992; 267: 114959.
  • 78
    Stec WJ, Zon G, Uznanski B. Reversed-phase high-performance liquid chromatographic separation of diastereomeric phosphorothioate analogues of oligodeoxyribonucleotides and other backbone-modified congeners of DNA. J. Chromatogr. 1985; 326: 26380.
  • 79
    Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucletide targeted against C-raf kinase. Nat. Med. 1996; 2: 66875.
  • 80
    Gleave M, Tolcher A, Miyake H et al. Progression to androgen-independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin. Cancer Res. 1999; 5: 28918.
  • 81
    Miyake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J. Natl. Cancer Inst. 2000; 92: 3441.
  • 82
    Miyake H, Hara I, Arakawa S, Kamidono S. Stress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin but not by glycosylation inhibitor, tunicamycin in human prostate cancer cells. J. Cell. Biochem. 2000; 77: 396408.
  • 83
    Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int. J. Cancer 2001; 91: 84650.
  • 84
    Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994; 372: 3335.
  • 85
    Monia BP, Lesnik EA, Gonzalez C et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 1993; 268: 1451422.
  • 86
    McKay RA, Cummins LL, Graham MJ et al. Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2′-O-propyl modifications. Nucleic Acids Res. 1996; 24: 41117.
  • 87
    Zellweger T, Miyake H, Cooper S et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy) ethyl chemistry. J. Pharmacol. Exp. Ther. 2001; 298: 93440.
  • 88
    Kiprianou N, King ED, Bradbury D, Rhee JG. Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer 1997; 70: 3418.
  • 89
    Miyake H, Hara I, Kamidono S, Gleave ME. Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. Int. J. Urol. 2001; 8: 33749.
  • 90
    Zangemeister-Wittke U, Leech SH, Olie RA et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 2000; 6: 254755.
  • 91
    Gautschi O, Tschopp S, Olie RA et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J. Natl. Cancer Inst. 2001; 93: 46371.
  • 92
    Yamanaka K, Miyake H, Zangemeister-Wittke U, Jansen B, Gleave ME. Novel bispecific antisense oligonucleotides inhibiting both bcl-2 and bcl-xL expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells. J. Urol. 2004; 170 (Suppl.): 287.
  • 93
    Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995; 16: 334.
  • 94
    Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 3004.
  • 95
    Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997; 32: 28493.
  • 96
    Yuen AR, Halsey J, Fisher GA et al. Phase I study of an antisense oligonucleotide to protein-kinase C-alpha (ISIS3521/CGP64128A) in patients with cancer. Clin. Cancer Res. 1999; 5: 335763.
  • 97
    Nylandested J, Rohde M, Brand K, Bastholm L, Elling F, Jaattela M. Selective depletion of heat shock protein 70 (Hsp 70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc. Natl. Acad. Sci. USA 2000; 97: 78716.
  • 98
    Kondo Y, Koga S, Komata T, Kondo S. Treatment of prostate cancer in vitro and in vivo with 2–5A-anti-telomerase RNA component. Oncogene 2000; 19: 220511.